Highlights from AGS: New Surgical Devices,

Size: px

Start display at page:

Download "Highlights from AGS: New Surgical Devices,"

Augustine Rodgers
6 years ago
Views:

1 SEARCH OIS... Keeping an Eye on Innovation Through Breaking News in Ophthalmology. Highlights from AGS: New Surgical Devices, Novel Therapeutics March 9, 2016 By Michelle Dalton Share 0 Share 4 Tweet Share 3 1 of 7 4/23/16 9:38 AM

This year s American Glaucoma Society annual meeting feted novel medications designed to lower intraocular pressure (IOP) in patients with glaucoma.

2 This year s American Glaucoma Society annual meeting feted novel medications designed to lower intraocular pressure (IOP) in patients with glaucoma. To date, available medications and surgery are designed to treat one of the primary risk factors elevated IOP. But they are not designed to directly target the underlying degeneration that s causing the vision loss. But a great deal of discussion also centered around the neurodegeneration of the retinal ganglion cells leads that leads vision loss. We have this panoply of different drops, implants, surgeries, different ways to lower the eye pressure. We know that lowering the eye pressure, in the end, helps slow down the disease, slow down the degeneration. If there were an eye pressure drug, like an eye pressure drop, that in addition to lowering eye pressure, also directly stimulated the survival and/or regeneration of the retinal ganglion cells and their axons, it would offer a dual-mode effect, a belt-and-suspenders kind of approach, said Jeffrey Goldberg, MD, professor and chair of ophthalmology, Stanford University, who presented on a combined Rho-associated protein kinase (ROCK) and norepinephrine transporter (NET) ophthalmic solution that is currently under FDA review: Aerie Pharmaceuticals Rhopressa (netarsudil ophthalmic solution 0.2%, formerly known as AR-13324). Dr. Goldberg s research was supported in part by Aerie. Goldberg noted that it would be fantastic if we had any drug that directly treated the degeneration of the 2 of 7 4/23/16 9:38 AM

3 eyedrop also conferred a neuroprotective or even regenerative capacity, that compound would have a great market advantage, and that s what Aerie is banking on with Rhopressa. Dr. Goldberg s group performed an optic nerve crush on young rats and applied Rhopressa or placebo three times daily for 10 days. The researchers found the compound lowered IOP as expected, but that retinal ganglion cell survival and optic nerve axon regeneration were signi_cantly higher in the treated group compared with placebo. The data also suggested that topical administration of Rhopressa may have associated molecular changes indicative of posterior drug activity, he said. Goldberg cautioned that what works in animal studies may not work in humans. We have to test these data in a larger animal with an eye more like a human; that would be the most plausible next step, he said, to determine if the rat _ndings can be con_rmed. Is this survival and regeneration effect in the optic nerve trauma model also seen in a glaucoma model? Dr. Goldberg questioned, indicating a direction for future investigation. And researchers need to determine the durability of the effect, he said. Our initial studies were short term. We really need to know about the long term. How long is the effect sustained? he asked. Is there a future to move such testing of neuroprotective or regenerative compounds to human trials? Goldberg believes there is. The time has arrived to start testing candidate neuroprotective therapies in glaucoma, he said. R e f e r e n c e : Topical administration of a ROCK/NET inhibitor promotes retinal ganglion cell survival and axon regeneration Share 0 Share 4 Tweet Share 3 3 of 7 4/23/16 9:38 AM

4 AAO Sees Good and Bad in Consolidation Gene Therapies Move One Step Closer to Reality Glaucoma Getting a Wake-Up Call Filed Under: News UPCOMING EVENT: EYE ON INNOVATION NEWSLETTER Get the latest news, podcasts and videos. Subscribe Today! 4 of 7 4/23/16 9:38 AM

5 Address SUBSCRIBE LATEST PODCASTS Avedro s Long Wait for FDA Approval is Over April 19, 2016 What are Allergan s Next Steps? April 13, 2016 KOL Corner: Can Complement Inhibitors Treat Macular Degeneration? April 6, 2016 LATEST TWEETS 5 of 7 4/23/16 9:38 AM

20h Ophthalmology Summit @OISTWEETS CEO Brent Saunders speaks on

Sponsorship Opportunities Speaking Opportunities Presenting

6 20h Ophthalmology CEO Brent Saunders speaks on GET INVOLVED About OIS Events News OISTV Podcasts Contact Us Sponsorship Opportunities Speaking Opportunities Presenting Companies Media & Press Advertise with OIS CONNECT WITH US 6 of 7 4/23/16 9:38 AM

7 2016 Ophthalmology Innovation Summit Powered by Healthegy Terms & Conditions Privacy Policy 7 of 7 4/23/16 9:38 AM

Building a Major Ophthalmic Pharmaceutical Company. Aerie Pharmaceuticals, Inc. July 13, 2016

Building a Major Ophthalmic Pharmaceutical Company Aerie Pharmaceuticals, Inc. July 13, 2016 1 Important Information Any discussion of the potential use or expected success of our product candidates is